J Liver Cancer.  2025 Mar;25(1):31-40. 10.17998/jlc.2025.02.16.

Recent advances and issues in imaging modalities for hepatocellular carcinoma surveillance

• Lee DH

• KMID: 2567062
• DOI: http://doi.org/10.17998/jlc.2025.02.16

Abstract

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide. Early detection via surveillance plays a crucial role in enabling curative treatment and improving survival rates. Since the initial randomized controlled trial, biannual ultrasound (US) has been established as the standard surveillance method because of its accessibility, safety, and low cost. However, US has some limitations, including operator dependency, suboptimal sensitivity for early-stage HCC, and challenges such as a limited sonic window that may result in inadequate examination. Alternative imaging modalities, including contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI), have demonstrated higher sensitivity for detecting very early-stage HCC. Recent advancements, such as low-dose CT with deep learning-based reconstruction, have enhanced the safety and feasibility of CT-based surveillance by reducing radiation exposure and amount of contrast media. MRI, particularly with gadoxetic acid or abbreviated protocols, offers superior tissue contrast and sensitivity, although its accessibility and cost remain challenges. Tailored surveillance strategies based on individual risk profiles and integration of advanced imaging technologies have the potential to enhance the detection performance and cost-effectiveness. This review highlights the recent developments in imaging technologies for HCC surveillance, focusing on their respective strengths and limitations.

Keyword

Carcinoma, hepatocellular; Diagnostic imaging; Surveillance

Reference

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71:209–249.

2. Korean Liver Cancer Association (KLCA); National Cancer Center (NCC) Korea. 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clin Mol Hepatol. 2022; 28:583–705.

3. Korean Liver Cancer Association (KLCA); National Cancer Center (NCC) Korea. 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. J Liver Cancer. 2023; 23:1–120.

4. Singal AG, Llovet JM, Yarchoan M, Mehta N, Heimbach JK, Dawson LA, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023; 78:1922–1965.

5. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of hepatocellular carcinoma. J Hepatol. 2025; 82:315–374.

6. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004; 130:417–422.

7. Santi V, Trevisani F, Gramenzi A, Grignaschi A, Mirici-Cappa F, Del Poggio P, et al. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol. 2010; 53:291–297.

8. Trinchet JC, Chaffaut C, Bourcier V, Degos F, Henrion J, Fontaine H, et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology. 2011; 54:1987–1997.

9. Kim HY, Nam JY, Lee JH, Lee HA, Chang Y, Lee HY, et al. Intensity of surveillance for hepatocellular carcinoma determines survival in patients at risk in a hepatitis B-endemic area. Aliment Pharmacol Ther. 2018; 47:1490–1501.

10. Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009; 30:37–47.

11. Kim SY, An J, Lim YS, Han S, Lee JY, Byun JH, et al. MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma. JAMA Oncol. 2017; 3:456–463.

12. Yoon JH, Lee JM, Lee DH, Joo I, Jeon JH, Ahn SJ, et al. A comparison of biannual two-phase low-dose liver CT and US for HCC surveillance in a group at high risk of HCC development. Liver Cancer. 2020; 9:503–517.

13. Tzartzeva K, Obi J, Rich NE, Parikh ND, Marrero JA, Yopp A, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology. 2018; 154:1706–1718. e1.

14. Fetzer DT, Rodgers SK, Harris AC, Kono Y, Wasnik AP, Kamaya A, et al. Screening and surveillance of hepatocellular carcinoma: an introduction to ultrasound liver imaging reporting and data system. Radiol Clin North Am. 2017; 55:1197–1209.

15. Morgan TA, Maturen KE, Dahiya N, Sun MRM, Kamaya A; American College of Radiology Ultrasound Liver Imaging and Reporting Data System (US LI-RADS) Working Group. US LI-RADS: ultrasound liver imaging reporting and data system for screening and surveillance of hepatocellular carcinoma. Abdom Radiol (NY). 2018; 43:41–55.

16. Choi HH, Rodgers SK, Fetzer DT, Wasnik AP, Millet JD, Morgan TA, et al. Ultrasound liver imaging reporting and data system (US LI-RADS): an overview with technical and practical applications. Acad Radiol. 2021; 28:1464–1476.

17. Kamaya A, Fetzer DT, Seow JH, Burrowes DP, Choi HH, Dawkins AA, et al. LI-RADS US surveillance version 2024 for surveillance of hepatocellular carcinoma: an update to the American College of Radiology US LI-RADS. Radiology. 2024; 313:e240169.

18. Son JH, Choi SH, Kim SY, Jang HY, Byun JH, Won HJ, et al. Validation of US liver imaging reporting and data system version 2017 in patients at high risk for hepatocellular carcinoma. Radiology. 2019; 292:390–397.

19. Chong N, Schoenberger H, Yekkaluri S, Fetzer DT, Rich NE, Yokoo T, et al. Association between ultrasound quality and test performance for HCC surveillance in patients with cirrhosis: a retrospective cohort study. Aliment Pharmacol Ther. 2022; 55:683–690.

20. Kang JH, Kim NH, Kim DH, Choi Y, Choi JI. Ultrasound LI-RADS visualization scores on surveillance ultrasound for hepatocellular carcinoma: a systematic review with meta-analysis. Ultrasound Med Biol. 2023; 49:2205–2212.

21. Park MK, Lee DH, Hur BY, Lee HC, Lee YB, Yu SJ, et al. Effectiveness of US surveillance of hepatocellular carcinoma in chronic hepatitis B: US LI-RADS visualization score. Radiology. 2023; 307:e222106.

22. Schoenberger H, Chong N, Fetzer DT, Rich NE, Yokoo T, Khatri G, et al. Dynamic changes in ultrasound quality for hepatocellular carcinoma screening in patients with cirrhosis. Clin Gastroenterol Hepatol. 2022; 20:1561–1569.e4.

23. Tiyarattanachai T, Fetzer DT, Kamaya A. Multicenter study of ACR ultrasound LI-RADS visualization scores on serial examinations: implications for surveillance strategies. AJR Am J Roentgenol. 2022; 219:445–452.

24. Tiyarattanachai T, Bird KN, Lo EC, Mariano AT, Ho AA, Ferguson CW, et al. Ultrasound liver imaging reporting and data system (US LI-RADS) visualization score: a reliability analysis on inter-reader agreement. Abdom Radiol (NY). 2021; 46:5134–5141.

25. Kiri L, Abdolell M, Costa AF, Keough V, Rowe J, Butt R, et al. US LI-RADS visualization score: interobserver variability and association with cause of liver disease, sex, and body mass index. Can Assoc Radiol J. 2022; 73:68–74.

26. Park HJ, Kim SY. Imaging modalities for hepatocellular carcinoma surveillance: expanding horizons beyond ultrasound. J Liver Cancer. 2020; 20:99–105.

27. Kudo M, Ueshima K, Osaki Y, Hirooka M, Imai Y, Aso K, et al. B-mode ultrasonography versus contrast-enhanced ultrasonography for surveillance of hepatocellular carcinoma: a prospective multicenter randomized controlled trial. Liver Cancer. 2019; 8:271–280.

28. Park JH, Park MS, Lee SJ, Jeong WK, Lee JY, Park MJ, et al. Contrast-enhanced US with perfluorobutane for hepatocellular carcinoma surveillance: a multicenter diagnostic trial (SCAN). Radiology. 2019; 292:638–646.

29. Pocha C, Dieperink E, McMaken KA, Knott A, Thuras P, Ho SB. Surveillance for hepatocellular cancer with ultrasonography vs. computed tomography -- a randomised study. Aliment Pharmacol Ther. 2013; 38:303–312.

30. Preston DL, Ron E, Tokuoka S, Funamoto S, Nishi N, Soda M, et al. Solid cancer incidence in atomic bomb survivors: 1958-1998. Radiat Res. 2007; 168:1–64.

31. Cha MJ, Kang DY, Lee W, Yoon SH, Choi YH, Byun JS, et al. Hypersensitivity reactions to iodinated contrast media: a multicenter study of 196 081 patients. Radiology. 2019; 293:117–124.

32. Koo JH, Lee M, Kim EH, Oh HJ, Lim JS, Hyung WJ, et al. Harmful effect of repetitive intravenous iodinated contrast media administration on the long-term renal function of patients with early gastric cancer. Sci Rep. 2023; 13:19448.

33. Yoon JH, Chang W, Lee ES, Lee SM, Lee JM. Double low-dose dual-energy liver CT in patients at high-risk of HCC: a prospective, randomized, single-center study. Invest Radiol. 2020; 55:340–348.

34. Akagi M, Nakamura Y, Higaki T, Narita K, Honda Y, Zhou J, et al. Deep learning reconstruction improves image quality of abdominal ultra-high-resolution CT. Eur Radiol. 2019; 29:6163–6171.

35. Nakamura Y, Narita K, Higaki T, Akagi M, Honda Y, Awai K. Diagnostic value of deep learning reconstruction for radiation dose reduction at abdominal ultra-high-resolution CT. Eur Radiol. 2021; 31:4700–4709.

36. Jensen CT, Gupta S, Saleh MM, Liu X, Wong VK, Salem U, et al. Reduced-dose deep learning reconstruction for abdominal CT of liver metastases. Radiology. 2022; 303:90–98.

37. Park S, Yoon JH, Joo I, Yu MH, Kim JH, Park J, et al. Image quality in liver CT: low-dose deep learning vs standard-dose model-based iterative reconstructions. Eur Radiol. 2022; 32:2865–2874.

38. Lee DH, Lee JM, Lee CH, Afat S, Othman A. Image quality and diagnostic performance of low-dose liver CT with deep learning reconstruction versus standard-dose CT. Radiol Artif Intell. 2024; 6:e230192.

39. Kang HJ, Lee JM, Ahn C, Bae JS, Han S, Kim SW, et al. Low dose of contrast agent and low radiation liver computed tomography with deep-learning-based contrast boosting model in participants at high-risk for hepatocellular carcinoma: prospective, randomized, double-blind study. Eur Radiol. 2023; 33:3660–3670.

40. Yoshida K, Nagayama Y, Funama Y, Ishiuchi S, Motohara T, Masuda T, et al. Low tube voltage and deep-learning reconstruction for reducing radiation and contrast medium doses in thin-slice abdominal CT: a prospective clinical trial. Eur Radiol. 2024; 34:7386–7396.

41. Lee YJ, Lee JM, Lee JS, Lee HY, Park BH, Kim YH, et al. Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis. Radiology. 2015; 275:97–109.

42. Huh J, Kim SY, Yeh BM, Lee SS, Kim KW, Wu EH, et al. Troubleshooting arterial-phase MR images of gadoxetate disodium-enhanced liver. Korean J Radiol. 2015; 16:1207–1215.

43. Marks RM, Ryan A, Heba ER, Tang A, Wolfson TJ, Gamst AC, et al. Diagnostic per-patient accuracy of an abbreviated hepatobiliary phase gadoxetic acid-enhanced MRI for hepatocellular carcinoma surveillance. AJR Am J Roentgenol. 2015; 204:527–535.

44. Besa C, Lewis S, Pandharipande PV, Chhatwal J, Kamath A, Cooper N, et al. Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid. Abdom Radiol (NY). 2017; 42:179–190.

45. Tillman BG, Gorman JD, Hru JM, Lee MH, King MC, Sirlin CB, et al. Diagnostic per-lesion performance of a simulated gadoxetate disodium-enhanced abbreviated MRI protocol for hepatocellular carcinoma screening. Clin Radiol. 2018; 73:485–493.

46. Gupta P, Soundararajan R, Patel A, Kumar-M P, Sharma V, Kalra N. Abbreviated MRI for hepatocellular carcinoma screening: a systematic review and meta-analysis. J Hepatol. 2021; 75:108–119.

47. Maung ST, Deepan N, Decharatanachart P, Chaiteerakij R. Abbreviated MRI for hepatocellular carcinoma surveillance - a systematic review and meta-analysis. Acad Radiol. 2024; 31:3142–3156.

48. Park HJ, Seo N, Kim SY. Current landscape and future perspectives of abbreviated MRI for hepatocellular carcinoma surveillance. Korean J Radiol. 2022; 23:598–614.

49. Khatri G, Pedrosa I, Ananthakrishnan L, de Leon AD, Fetzer DT, Leyendecker J, et al. Abbreviated-protocol screening MRI vs. complete-protocol diagnostic MRI for detection of hepatocellular carcinoma in patients with cirrhosis: an equivalence study using LI-RADS v2018. J Magn Reson Imaging. 2020; 51:415–425.

50. Ahn YH, Kang DY, Park SB, Kim HH, Kim HJ, Park GY, et al. Allergic-like hypersensitivity reactions to gadolinium-based contrast agents: an 8-year cohort study of 154 539 patients. Radiology. 2022; 303:329–336.

51. Choi JW, Moon WJ. Gadolinium deposition in the brain: current updates. Korean J Radiol. 2019; 20:134–147.

52. Kim YK, Kim YK, Park HJ, Park MJ, Lee WJ, Choi D. Noncontrast MRI with diffusion-weighted imaging as the sole imaging modality for detecting liver malignancy in patients with high risk for hepatocellular carcinoma. Magn Reson Imaging. 2014; 32:610–618.

53. Han S, Choi JI, Park MY, Choi MH, Rha SE, Lee YJ. The diagnostic performance of liver MRI without intravenous contrast for detecting hepatocellular carcinoma: a case-controlled feasibility study. Korean J Radiol. 2018; 19:568–577.

54. Park HJ, Jang HY, Kim SY, Lee SJ, Won HJ, Byun JH, et al. Non-enhanced magnetic resonance imaging as a surveillance tool for hepatocellular carcinoma: comparison with ultrasound. J Hepatol. 2020; 72:718–724.

55. Chan MV, Huo YR, Trieu N, Mitchelle A, George J, He E, et al. Noncontrast MRI for hepatocellular carcinoma detection: a systematic review and meta-analysis - a potential surveillance tool? Clin Gastroenterol Hepatol. 2022; 20:44–56.e2.

56. Kim DH, Yoon JH, Choi MH, Lee CH, Kang TW, Kim HA, et al. Comparison of non-contrast abbreviated MRI and ultrasound as surveillance modalities for HCC. J Hepatol. 2024; 81:461–470.

57. Arguedas MR, Chen VK, Eloubeidi MA, Fallon MB. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol. 2003; 98:679–690.

58. Cucchetti A, Trevisani F, Cescon M, Ercolani G, Farinati F, Poggio PD, et al. Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian liver cancer population. J Hepatol. 2012; 56:1089–1096.

59. Ruggeri M. Hepatocellular carcinoma: cost-effectiveness of screening. A systematic review. Risk Manag Healthc Policy. 2012; 5:49–54.

60. Goossens N, Singal AG, King LY, Andersson KL, Fuchs BC, Besa C, et al. Cost-effectiveness of risk score-stratified hepatocellular carcinoma screening in patients with cirrhosis. Clin Transl Gastroenterol. 2017; 8:e101.

61. Kim HL, An J, Park JA, Park SH, Lim YS, Lee EK. Magnetic resonance imaging is cost-effective for hepatocellular carcinoma surveillance in high-risk patients with cirrhosis. Hepatology. 2019; 69:1599–1613.